159 related articles for article (PubMed ID: 33956757)
21. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
22. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
23. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.
Lum LC; Borja-Tabora CF; Breiman RF; Vesikari T; Sablan BP; Chay OM; Tantracheewathorn T; Schmitt HJ; Lau YL; Bowonkiratikachorn P; Tam JS; Lee BW; Tan KK; Pejcz J; Cha S; Gutierrez-Brito M; Kaltenis P; Vertruyen A; Czajka H; Bojarskas J; Brooks WA; Cheng SM; Rappaport R; Baker S; Gruber WC; Forrest BD
Vaccine; 2010 Feb; 28(6):1566-74. PubMed ID: 20003918
[TBL] [Abstract][Full Text] [Related]
24. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
Nakayama T; Eda M; Hirano M; Goto W
Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
27. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders.
Gentile I; Bravaccio C; Bonavolta R; Zappulo E; Scarica S; Riccio MP; Settimi A; Portella G; Pascotto A; Borgia G
In Vivo; 2013; 27(3):377-82. PubMed ID: 23606694
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study.
Woudenberg T; van der Maas NAT; Knol MJ; de Melker H; van Binnendijk RS; Hahné SJM
J Infect Dis; 2017 Apr; 215(8):1181-1187. PubMed ID: 28368471
[TBL] [Abstract][Full Text] [Related]
29. Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s.
Geier DA; Kern JK; Geier MR
BMC Pediatr; 2019 Sep; 19(1):325. PubMed ID: 31506095
[TBL] [Abstract][Full Text] [Related]
30. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
[TBL] [Abstract][Full Text] [Related]
32. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Krow-Lucal E; Marin M; Shepersky L; Bahta L; Loehr J; Dooling K
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(46):1465-1470. PubMed ID: 36395065
[TBL] [Abstract][Full Text] [Related]
33. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
Platt H; Tochihara S; Oda Y; Ueda K
Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
[TBL] [Abstract][Full Text] [Related]
34. Impact of pregnancy vaccine uptake and socio-demographic determinants on subsequent childhood Measles, Mumps and Rubella vaccine uptake: A UK birth cohort study.
Skirrow H; Foley K; Bedford H; Lewis C; Whittaker E; Costelloe C; Saxena S
Vaccine; 2024 Jan; 42(2):322-331. PubMed ID: 38072757
[TBL] [Abstract][Full Text] [Related]
35. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
Knutsson N; Jansson UB; Alm B
Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
[TBL] [Abstract][Full Text] [Related]
36. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
[TBL] [Abstract][Full Text] [Related]
37. Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers.
Hyle EP; Rao SR; Bangs AC; Gastañaduy P; Fiebelkorn AP; Hagmann SHF; Walker AT; Walensky RP; Ryan ET; LaRocque RC
JAMA Pediatr; 2020 Feb; 174(2):e194515. PubMed ID: 31816033
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
Usonis V; Bakasenas V; Chitour K; Clemens R
Infection; 1998; 26(4):222-6. PubMed ID: 9717679
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014.
Chang C; Mo X; Hu P; Liang W; Ma H; An Z; Liu J; Zheng H
Vaccine; 2015 Jun; 33(28):3223-7. PubMed ID: 25989448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
